| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Alvelestat selectively targets and inhibits neutrophil elastase (NE), a serine protease released from activated neutrophils. It binds to neutrophil elastase with high affinity, demonstrating a pIC₅₀ of 7.9 nM, a Ki of 9.4 nM, and a Kd of 9.5 nM. By inhibiting NE, the compound reduces neutrophil extracellular trap (NET) formation and associated tissue damage.
|
|---|---|
| ln Vitro |
In vitro, Alvelestat (20 μg/mL; 16 hours) treatment decreases TNF-α, IL-6, and IL-1β levels and decreases cell death [2].
In cell-free enzyme assays, alvelestat inhibits human neutrophil elastase with a Ki of 9.4 nM and a Kd of 9.5 nM. The compound demonstrates high selectivity for neutrophil elastase over other serine proteases. Enzyme inhibition is measured using standard fluorogenic or chromogenic peptide substrates, with activity determined by monitoring substrate cleavage. In vitro, alvelestat at 20 µg/mL for 16 hours decreases cell death and reduces levels of IL-1β, IL-6, and TNF-α in HBE and A549 cells. |
| ln Vivo |
In cell-based assays, alvelestat is evaluated using relevant cell lines such as HBE (human bronchial epithelial) and A549 (lung adenocarcinoma) cells. Cells are treated with the compound, and inflammatory cytokine production (IL-1β, IL-6, TNF-α) is measured by ELISA or multiplex assays. Neutrophil elastase activity in cell supernatants is assessed using specific substrates. The compound's ability to inhibit NET formation can also be evaluated in neutrophil cultures.
|
| Enzyme Assay |
Alvelestat has been evaluated in multiple Phase II clinical trials for various indications. Clinical trials include NCT03636347 (Alpha-1 Antitrypsin Deficiency, Emphysema, COPD), NCT04539795 (COVID-19), NCT03679598 (Alpha-1 Antitrypsin Deficiency), NCT01054170 (COPD), and NCT00949975. These studies assess the compound's efficacy, safety, and pharmacokinetics in patient populations.
|
| References |
| Molecular Formula |
C32H30F3N5O7S2
|
|---|---|
| Molecular Weight |
717.735115528107
|
| Exact Mass |
717.154
|
| CAS # |
1240425-05-1
|
| Related CAS # |
Alvelestat;848141-11-7
|
| PubChem CID |
46861622
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
7.087
|
| tPSA |
187.08
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
49
|
| Complexity |
1310
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C1C=CC(C)=CC=1)(O)(=O)=O.CC1=C(C2=CC=NN2C)C=C(C(=O)NCC2N=CC(S(=O)(=O)C)=CC=2)C(=O)N1C1C=CC=C(C(F)(F)F)C=1
|
| InChi Key |
YLZZBCWZQPXIHL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H22F3N5O4S.C7H8O3S/c1-15-20(22-9-10-31-32(22)2)12-21(23(34)30-13-17-7-8-19(14-29-17)38(3,36)37)24(35)33(15)18-6-4-5-16(11-18)25(26,27)28;1-6-2-4-7(5-3-6)11(8,9)10/h4-12,14H,13H2,1-3H3,(H,30,34);2-5H,1H3,(H,8,9,10)
|
| Chemical Name |
4-methylbenzenesulfonic acid;6-methyl-5-(2-methylpyrazol-3-yl)-N-[(5-methylsulfonylpyridin-2-yl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3933 mL | 6.9663 mL | 13.9326 mL | |
| 5 mM | 0.2787 mL | 1.3933 mL | 2.7865 mL | |
| 10 mM | 0.1393 mL | 0.6966 mL | 1.3933 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.